Zentalis Pharmaceuticals (NASDAQ:ZNTL) Insider Vincent Vultaggio Sells 29,951 Shares

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Vincent Vultaggio sold 29,951 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the sale, the insider directly owned 156,779 shares of the company’s stock, valued at approximately $380,972.97. This represents a 16.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vincent Vultaggio also recently made the following trade(s):

• On Tuesday, February 10th, Vincent Vultaggio sold 6,894 shares of Zentalis Pharmaceuticals stock. The shares were sold at an average price of $2.42, for a total value of $16,683.48.
• On Monday, February 9th, Vincent Vultaggio sold 3,379 shares of Zentalis Pharmaceuticals stock. The shares were sold at an average price of $2.39, for a total value of $8,075.81.
• On Tuesday, February 3rd, Vincent Vultaggio sold 556 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $2.52, for a total value of $1,401.12.
• On Monday, February 2nd, Vincent Vultaggio sold 2,540 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $2.55, for a total value of $6,477.00.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $2.40 on Wednesday. The firm has a market cap of $173.40 million, a price-to-earnings ratio of -1.16 and a beta of 1.73. The firm’s fifty day moving average price is $2.12 and its 200 day moving average price is $1.73. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.01 and a 1-year high of $3.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12. As a group, analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ZNTL has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Leerink Partners reissued a “market perform” rating and set a $2.00 price target on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Finally, Morgan Stanley lowered their price target on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $5.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Tybourne Capital Management HK Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 53.7% during the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after purchasing an additional 516,666 shares during the last quarter. Acadian Asset Management LLC increased its stake in Zentalis Pharmaceuticals by 4.7% in the second quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company’s stock valued at $3,241,000 after purchasing an additional 124,985 shares during the last quarter. Savant Capital LLC purchased a new position in Zentalis Pharmaceuticals during the second quarter worth about $59,000. Y Intercept Hong Kong Ltd purchased a new position in Zentalis Pharmaceuticals during the second quarter worth about $38,000. Finally, Corient Private Wealth LLC acquired a new stake in Zentalis Pharmaceuticals in the 2nd quarter worth about $83,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.